PL3413897T3 - Sposoby leczenia i profilaktyki HIV i AIDS - Google Patents

Sposoby leczenia i profilaktyki HIV i AIDS

Info

Publication number
PL3413897T3
PL3413897T3 PL17706102.5T PL17706102T PL3413897T3 PL 3413897 T3 PL3413897 T3 PL 3413897T3 PL 17706102 T PL17706102 T PL 17706102T PL 3413897 T3 PL3413897 T3 PL 3413897T3
Authority
PL
Poland
Prior art keywords
hiv
aids
prevention
treatment
methods
Prior art date
Application number
PL17706102.5T
Other languages
English (en)
Polish (pl)
Inventor
Daria Hazuda
Michael D. Miller
Jay A. Grobler
Deborah Anne Nicoll-Griffith
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of PL3413897T3 publication Critical patent/PL3413897T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
PL17706102.5T 2016-02-12 2017-02-10 Sposoby leczenia i profilaktyki HIV i AIDS PL3413897T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (1)

Publication Number Publication Date
PL3413897T3 true PL3413897T3 (pl) 2023-10-02

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17706102.5T PL3413897T3 (pl) 2016-02-12 2017-02-10 Sposoby leczenia i profilaktyki HIV i AIDS

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20250136420A (enExample)
CN (2) CN108697727A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TWI822652B (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
US12227536B2 (en) * 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
PH12021500034A1 (en) * 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
JP7700096B2 (ja) 2019-07-27 2025-06-30 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
PL219609B1 (pl) 2003-02-19 2015-06-30 Masanori Baba Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
AU2020328518A1 (en) * 2019-08-13 2022-03-10 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
HRP20230935T1 (hr) 2023-11-24
US20200101098A1 (en) 2020-04-02
JP2022062170A (ja) 2022-04-19
HUE063532T2 (hu) 2024-01-28
CN108697727A (zh) 2018-10-23
MX2018009763A (es) 2018-11-29
SV2018005733A (es) 2018-12-14
JP6810972B2 (ja) 2021-01-13
HK1257347A1 (en) 2019-10-18
JOP20170038B1 (ar) 2021-08-17
KR102317570B1 (ko) 2021-10-25
JP7021314B2 (ja) 2022-02-16
LT3413897T (lt) 2023-08-25
US10537589B2 (en) 2020-01-21
KR20250136420A (ko) 2025-09-16
AU2020202866A1 (en) 2020-05-21
AU2017217656A1 (en) 2018-08-23
ZA201805073B (en) 2019-05-29
RS64448B1 (sr) 2023-09-29
US20250073254A1 (en) 2025-03-06
PH12018501712A1 (en) 2019-05-15
PT3413897T (pt) 2023-08-28
US20220331350A1 (en) 2022-10-20
US11337991B2 (en) 2022-05-24
CA3013473C (en) 2021-10-26
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
AU2020202866B2 (en) 2022-04-07
NZ784982A (en) 2025-03-28
EP3413897B1 (en) 2023-06-14
KR20220126787A (ko) 2022-09-16
JP7559175B6 (ja) 2024-10-22
FI3413897T3 (fi) 2023-08-25
DOP2018000183A (es) 2018-12-31
JP2021001189A (ja) 2021-01-07
AU2022201686B2 (en) 2024-08-08
SI3413897T1 (sl) 2023-11-30
DK3413897T3 (da) 2023-09-18
CL2018002150A1 (es) 2018-12-14
MX2022002925A (es) 2023-02-10
IL260874A (enExample) 2018-09-20
MX390604B (es) 2025-03-20
MD3413897T2 (ro) 2023-11-30
EA201891814A1 (ru) 2019-01-31
BR112018016349A2 (pt) 2018-12-26
US20180055867A1 (en) 2018-03-01
MY197090A (en) 2023-05-24
UA126375C2 (uk) 2022-09-28
US12171776B2 (en) 2024-12-24
JP2019504857A (ja) 2019-02-21
JP2024001206A (ja) 2024-01-09
CN113509480A (zh) 2021-10-19
JP7559175B2 (ja) 2024-10-01
NZ745065A (en) 2023-11-24
GEP20217231B (en) 2021-03-25
EP3413897A1 (en) 2018-12-19
TN2018000267A1 (en) 2020-01-16
AU2022201686A1 (en) 2022-03-31
ES2953535T3 (es) 2023-11-14
KR20210049201A (ko) 2021-05-04
CA3013473A1 (en) 2017-08-17
TWI822652B (zh) 2023-11-21
KR20180108815A (ko) 2018-10-04
MX2022002924A (es) 2022-12-15
TW201731514A (zh) 2017-09-16
SG11201806783WA (en) 2018-09-27
TW202417010A (zh) 2024-05-01
IL260874B2 (en) 2023-10-01
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
NL301322I2 (nl) Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
PL3402888T3 (pl) Środki i sposoby leczenia hbv
IL262301A (en) Liposomal preparation and methods of treatment
IL257663B (en) Oral care compositions and methods of use
PL3413897T3 (pl) Sposoby leczenia i profilaktyki HIV i AIDS
LT3684377T (lt) Hepatito b infekcijos gydymo būdai
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
SI3347352T1 (sl) Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
IL246678A0 (en) Azepane derivatives and methods of treating hepatitis b infections
HRP20181130T1 (hr) Postupci za liječenje infekcija virusom filoviridae
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
PT3142637T (pt) Formulações e métodos de tratamento de queratina
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PT3548033T (pt) Compostos e respectivos métodos de utilização
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
IL263368A (en) Prevention and treatment of viral infections
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
PL3204030T3 (pl) Terapia skojarzona zakażenia hbv i hdv
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
IL313083A (en) Terlipressin compositions and their methods of use
EP3134108A4 (en) Agents and methods of treatment